Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Payables (2022 - 2025)

Historic Payables for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $5.8 million.

  • Day One Biopharmaceuticals' Payables rose 9151.47% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.8 million, marking a year-over-year increase of 9151.47%. This contributed to the annual value of $3.3 million for FY2024, which is 2663.04% up from last year.
  • As of Q3 2025, Day One Biopharmaceuticals' Payables stood at $5.8 million, which was up 9151.47% from $5.1 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' Payables' 5-year high stood at $16.0 million during Q4 2022, with a 5-year trough of $439000.0 in Q2 2022.
  • For the 4-year period, Day One Biopharmaceuticals' Payables averaged around $4.5 million, with its median value being $4.0 million (2022).
  • Data for Day One Biopharmaceuticals' Payables shows a peak YoY increase of 93986.33% (in 2023) and a maximum YoY decrease of 8384.95% (in 2023) over the last 5 years.
  • Over the past 4 years, Day One Biopharmaceuticals' Payables (Quarter) stood at $16.0 million in 2022, then crashed by 83.85% to $2.6 million in 2023, then rose by 26.63% to $3.3 million in 2024, then surged by 77.13% to $5.8 million in 2025.
  • Its Payables stands at $5.8 million for Q3 2025, versus $5.1 million for Q2 2025 and $2.5 million for Q1 2025.